Actually my background is the genomics analysis sector. Your po'd comment is so off base. I understand the economics and challenges of lab testing and data analysis.
Apparently you're not familiar with the medical testing industry. It is extremely competitive with op-ex being severely intensive. OPKO will need to divert more resources to stay competitive with the big boys, while diluting the drug pipeline or acquisitions. Not a good move for the Dr.
Pre Roche investor here. Of course I am severely underwater with this holding, I believe that this is a long- term investment. As you listed both the positives and negatives, another reason for the sp performance is the presence of Roche, which takes the possibility of of an acquisition by an another company out of play.
The other issue is the modest profit levels associated with general medical testing. Whether 4K will bring greater share price remains uncertain. My position is fto justify future higher share price the execution of diagnostics coverage and pharmaceutical approvals has to click. Otherwise the shares are fully valued at best.
It has little to do with drug category as it has with potential revenue and earnings, as well as defensible patents. AKB-6548 is a promising candidate as an acquisition to a larger pharm. As they complete more successful trials I hope to see ~$30 sp.
The clinical value of GeneDx is not, on its own, going to be a game changer for OPK. More to this the market is full of competitive labs with sequencers competing for this business. The complexity of matching patients to test to targeted therapies requires a multiple collaboration with drug companies, health care providers, insurers and data.
Yeah, I too also wondered how one with a physician's license would be hyping here. Also the quality and range of his comments leaves me suspect for someone with that status.
Like this last post, I too, currently own shares in OPK(underwater). I am so displeased with both the longs and shorts who will resort to insults if the opinions clash with theirs.
Just the facts please. Whether they carry your position or not.
No labels just well reasoned opinions supported by accurate facts.
One reason why the sp is in the dog house is the ISS rating.WIth 10 being the worst for Audit, Board composition, and 8 for compensation, the average risk rating is 9. High risk for any institutional investor.
Charter or drug discovery, VC, or testing and analysis lab. Unless at some point in time the plan is to divest into an IPO,
I also think that the BRLI acquisition was a bad decision and will become dilutive for future earnings. Regional labs are quickly morphing into point-of-care testing---see Abbott Labs buy into Alere. Coupled with the schizophrenia of is OPKO charter.
You are a mensch. The fix is in. Our entire economic and political system is fixed at the hard-working, common man expense.